Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES   JULY-AUGUST 2012 , Volume 15 , Number 4; Page(s) 926 To 936.
 
Paper: 

EFFECT OF CANNABINOID RECEPTOR ACTIVATION ON SPREADING DEPRESSION

 
 
Author(s):  KAZEMI HADI, RAHGOZAR MEHDI, SPECKMANN ERWIN JOSEF, GORJI ALI*
 
* INSTITUTE FOR PHYSIOLOGIE I, WESTFALISCHE WILHELMS-UNIVERSITY AT MUNSTER, MUNSTER, GERMANY
 
Abstract: 

Objective(s): The objective of this study was to evaluate the effect of cannabinoid on cortical spreading depression (CSD) in rat brain. Cannabis has been used for centuries for both symptomatic and prophylactic treatment of different types of headaches including migraine. CSD is believed to be a putative neuronal mechanism underlying migraine aura and subsequent pain.
Materials and Methods: The effects of Delta9-tetrahydrocannabinol (THC), as well as, cannabinoid CB1 and CB2 receptor agonists on CSD in rat neocortical slices were investigated. Furthermore, the effect of cannabinoid CB1 agonist was tested on field excitatory postsynaptic potentials (fEPSP) and long-term potentiation (LTP).
Results: HC (1-20 microM) dose dependently suppressed CSD amplitude, duration, and propagation velocity. Cannabinoid CB1 agonist, WIN 55, 212-2 mesylate (1-10 microM), also significantly suppressed all characteristic features of CSD. However, cannabinoid CB2 agonist, JWH-133 (1-20 microM), did not affect CSD. FEPSP and induction of LTP were suppressed by application of WIN55212-2.
Conclusion: Suppression of CSD by activation of CB1 receptors points to the potential therapeutic effects of cannabinoids in migraine with aura. More research is needed before we know whether cannabinoids may be helpful in treating migraine pain.

 
Keyword(s): ENDOCANNABINOID, HEADACHE, MARIJUANA, MIGRAINE, PHARMACOTHERAPY, SYNAPTIC TRANSMISSION
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 79
 
Latest on Blog
Enter SID Blog